| Original language | English |
|---|---|
| Pages (from-to) | 961-964 |
| Number of pages | 4 |
| Journal | Annals of Oncology |
| Volume | 31 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 1 Jul 2020 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of Oncology, Vol. 31, No. 7, 01.07.2020, p. 961-964.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure
T2 - a case report
AU - Michot, J. M.
AU - Albiges, L.
AU - Chaput, N.
AU - Saada, V.
AU - Pommeret, F.
AU - Griscelli, F.
AU - Balleyguier, C.
AU - Besse, B.
AU - Marabelle, A.
AU - Netzer, F.
AU - Merad, M.
AU - Robert, C.
AU - Barlesi, F.
AU - Gachot, B.
AU - Stoclin, A.
N1 - Funding Information: None declared. JMM reports sponsored research at Gustave Roussy Cancer Center with Abbvie, Agios, Amgen, Astex, AstraZeneca, Bayer, Beigene, Blueprint, Bristol-Myers Squibb, Boeringer Ingelheim, Celgene, Chugai, Forma, Genentech, GSK, H3 Biomedecine, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Oncopeptides AB, Roche, Sanofi, Taiho, and Xencor, outside the submitted work, and personal fees or travel grants or ad-board: Astex, Iqone, Mundipharma, and Bristol-Myers Squibb, outside the submitted work. BB reports sponsored research at Gustave Roussy Cancer Center with Abbvie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE immunotherapeutics, Pfizer, Pharma Mar, Roche-Genentech, Sanofi, Servier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, and Tolero Pharmaceuticals, outside the submitted work. CR reports personal fees for advisory boards from Bristol-Myers Squibb (BMS), Pierre Fabre, Novartis, Amgen, Merck, and Roche, outside the submitted work. FB reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda, outside the submitted work. AM reports sponsored research at Gustave Roussy Cancer Center with: Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 Biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor, outside the submitted work.
PY - 2020/7/1
Y1 - 2020/7/1
UR - http://www.scopus.com/inward/record.url?scp=85083292393&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2020.03.300
DO - 10.1016/j.annonc.2020.03.300
M3 - Letter
C2 - 32247642
AN - SCOPUS:85083292393
SN - 0923-7534
VL - 31
SP - 961
EP - 964
JO - Annals of Oncology
JF - Annals of Oncology
IS - 7
ER -